Registration opens for workshop of the European Network of Paediatric Research at the European Medicines Agency
Registration is now open for the sixth workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) which will take place at the EMA on 26 and 27 June 2014.
Registration is open until 13 June. The completed registration form should be sent to firstname.lastname@example.org. This workshop will not be broadcasted live.
The aim of the workshop is to strengthen communication between all stakeholders; it will provide an opportunity for representatives from regulatory authorities, industry, academia, clinical investigators and patient/parent organisations to be updated on Enpr-EMA’s efforts to foster high-quality paediatric drug research and to contribute to the ongoing development of research and clinical trials in the area of paediatric medicine.
The first day of the workshop will be open to all stakeholders including patient/parent organisations, network representatives, regulators and pharmaceutical industry staff responsible for paediatric studies. On the second day, the Enpr-EMA Coordinating Group will reflect on the outcomes of the first day, and will define priority tasks of the Coordinating Group and the Enpr-EMA Working Groups for 2014-2015.
Enpr-EMA is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children. Its main objective is to facilitate studies in order to increase the availability of medicinal products authorised for use in children, by:
- fostering high-quality, ethical research on the quality, safety and efficacy of medicines for use in children;
- helping with the recruitment of patients for clinical trials;
- enabling collaboration between networks and stakeholders;
- avoiding unnecessary duplication of studies;
- building up scientific and administrative competence at a European level;
- promoting European Commission framework programme applications.
Enpr-EMA holds a workshop each year at the European Medicines Agency.